BioPharmSignal logoBioPharmSignal

Biotech News

Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

Rhythm Pharmaceuticals (RYTM)Rhythm PharmaceuticalsEarnings

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 3, 2026 to report its third quarter 2026 financial results and provide a corporate update.

Related news

RYTMRhythm Pharmaceuticals2026-07-21 12:00 EST

Rhythm Pharmaceuticals to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026

RYTMRhythm Pharmaceuticals2026-08-04 11:01 EST

Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

CVRXCVRx2026-10-22 20:30 EST

CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026

LXRXLexicon Pharmaceuticals2026-07-30 12:30 EST

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

MISTMilestone Pharmaceuticals Inc.2026-08-12 11:08 EST

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Update

LXRXLexicon Pharmaceuticals2026-08-06 11:30 EST

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

MISTMilestone Pharmaceuticals Inc.2026-08-04 20:01 EST

Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026

VKTXViking Therapeutics2026-10-21 20:05 EST

Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026

MLYSMineralys Therapeutics2026-08-04 12:00 EST

Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026

EMBCEmbecta2026-07-23 21:00 EST

embecta to Report Fiscal Third Quarter Financial Results

View all latest news

Rhythm Pharmaceuticals

Rare Neuroendocrine Diseases Rhythm Pharmaceuticals develops and commercializes therapies for rare neuroendocrine disorders characterized by pathological hunger and severe obesity. Its programs focus on restoring melanocortin-4 receptor pathway signaling in genetically or structurally defined patient populations. IMCIVREE...

Recent company news

RYTMRhythm Pharmaceuticals2026-10-21 12:00 EST

Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026

RYTMRhythm Pharmaceuticals2026-10-13 23:30 EST

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

RYTMRhythm Pharmaceuticals2026-09-22 12:00 EST

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic Obesity

RYTMRhythm Pharmaceuticals2026-09-10 12:00 EST

Rhythm Pharmaceuticals Announces New Data Presentations at the European Society for Paediatric Endocrinology Meeting

RYTMRhythm Pharmaceuticals2026-08-24 12:00 EST

Rhythm Pharmaceuticals Announces MHLW Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity (HO) in Japan

Stock data

Close
88.62 USD
Market cap
5.79B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States